Press Releases

Date Title and Summary Additional Formats
Toggle Summary

Fate Therapeutics' iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs

San Diego, CA – Fate Therapeutics, Inc. announced today that the Company’s iPSC technology platform, developed with Sheng Ding, Ph.D., has been honored as the Top Innovation of 2009 by The Scientist and has received the 2009 North American Technology Innovation Award from Frost & Read All » 		View HTML
Toggle Summary

Fate Therapeutics Closes $30 Million Series B Financing

Led by OVP Venture Partners and Includes Syndicate of Corporate Investors Read All » 		View HTML
Toggle Summary

Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming

Development of Two Week Method for Generating Human Induced Pluripotent Stem Cells with 200-Fold Increase in Yield Read All » 		View HTML
Toggle Summary

Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of WNT Pathway

Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of WNT Pathway La Jolla, CA and Barcelona – Fate Therapeutics, Inc. announced today the presentation of data from its research on small molecule modulators of the Wnt pathway for Read All » 		View HTML
Toggle Summary

Fate Therapeutics Granted Exclusive License by The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration

La Jolla, CA – Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from The Regents of the University of California. These proprietary osteogenic agents were developed Read All » 		View HTML
Displaying 321 - 325 of 325 results

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.

MENU